TEMPERATURE CONTROLLED RADIOFREQUENCY FOR VULVOVAGINAL LAXITY

Red M. Alinsod evaluates the results of his study on the effectiveness of non-invasive transcutaneous temperature controlled radiofrequency for vulvovaginal rejuvenation

ABSTRACT
Objective: To evaluate the safety, tolerability, and clinical efficacy of non-invasive transcutaneous temperature controlled radiofrequency (TTCRF) for vulvovaginal rejuvenation and document ancillary beneficial effects of treatment.

Patients and methods: Subjects (n=23; age range 26-58 years, mean 43.6; 5 menopausal, 6 perimenopausal) were treated with mild to moderate primary or secondary vulvovaginal laxity. Associated conditions (organismic dysfunction, stress incontinence, atrophic vaginitis) were present in most subjects. Exclusion criteria included pelvic surgery within 5 years, pregnancy or planned pregnancy within the study period, recent abnormal Papanicolaou test result, and presence of vulvar lesions or any condition that may potentially interfere with the safe treatment. Informed consent was obtained from all subjects. Patients were treated up to three times at an interval of 4 to 6 weeks.

Outcome measures: Subject assessment via vaginal laxity questionnaire (VLQ) rating on a 7 point scale where 1=very loose and 7=very tight, and sexual satisfaction questionnaire (SSQ) rating on a six point scale where 1=none and 6=excellent, as well as observations of associated conditions such as incontinence, atrophic vaginitis, and orgasmic dysfunction.

Results: Median improvement of 5 points on the VLQ scale and 2.5 points on the SSQ scale were noted; results were statistically significant (p<0.05). The most pronounced outcomes manifested after initial treatment with additional improvement after each of the second and third treatments. Patients with orgasmic dysfunction, stress incontinence, and/or atrophic vaginitis noted substantial improvement regardless of number of treatments. Menopausal subjects were able to cease usage of vaginal estrogens.

Conclusion: TTCRF is safe, tolerable, and effective for vulvovaginal rejuvenation. Evidence suggests applications in the treatment of atrophic vaginitis, orgasmic dysfunction, and stress incontinence.

KEYWORDS
Vulvovaginal laxity, temperature-controlled radiofrequency, non-surgical vaginal rejuvenation

The vaginal wall predominantly consists of dense connective tissue that is heavily vascularized and through which many nerves pass, lined by a slightly keratinized, stratified squamous epithelium. The vulva, particularly the labia majora, is even more skin-like although generally more heavily vascularized and innervated than skin in most bodily regions. During vaginal delivery, stretching causes damage to the connective tissue that heals in a varying state of laxity that increases with each successive birth; the vulva is similarly affected. In addition, reductions in the quality of connective tissue due to neuroendocrine changes and age serve as contributing factors. This condition is rarely discussed in a clinical setting. Other conditions such as stress incontinence and atrophic vaginitis arise in conjunction with vulvovaginal laxity, as well as natural results of delivery trauma and advancing age. An additional consequence to vulvovaginal laxity is reduced sensation during coitus, with a potential negative effect on sexual satisfaction and quality of life.

The term ‘vulvovaginal laxity’ encompasses laxity of both the vaginal introitus and labia majora. Given that most people refer to the entire compound structure as ‘the vagina’ it stands to reason that ‘vaginal laxity’ and ‘vulvovaginal laxity’ will be used synonymously by some but it is important to note that, technically, ‘vaginal laxity’ does not involve the vulva specifically. Laxity of the vagina, specifically, is often referred to as pelvic organ prolapse but that term is also inaccurate because it refers to a more severe condition possibly involving vaginal and other genito-pelvic structures bulging into the vaginal canal and introitus, rather than laxity of the introitus itself.

To the patient, there are other notable characteristics of vulvovaginal laxity and the aesthetic appearance of the vagina may be perceived as significantly compromised, leading to self-consciousness. Laxity of the labia majora may be associated with discomfort and irritation when tight clothing is worn, as well as discomfort during intercourse. Orgasmic dysfunction, reduced friction during sex due to ‘looseness’, and other aspects of laxity-related changes are perceived to negatively impact the sexual experience in a variety of ways. So vaginal laxity or ‘looseness’ as a medical or aesthetic concern is not new; it is, however, only recently becoming socially acceptable as a topic of consideration. References to the vagina—structure, function, and associated problems—are now less taboo. Gynecological and urological issues that women may have been reluctant to address directly with physicians or even friends in the past are now commonly discussed. The vulva—especially the labia majora—has a much greater effect on sexual function than it is given credit for. The labia majora is often referred to as “hanging skin” and during coitus, with a potential negative effect on sexual satisfaction and quality of life.
past are somewhat out in the open and, as such, more comfortably discussed in a clinical setting. In the past, treatment of vulvovaginal laxity and related aspects lay within a short spectrum heavily weighted at the ends, with non-invasive (but minimally effective) Kegel exercises to strengthen the pelvic floor versus costly, invasive surgery at the other end. A 2012 physician member survey conducted by the International Urogynecological Association (IUGA) assessed the attitudes and practices regarding vaginal laxity\(^4\), of the 953 respondents, 84% stated belief that vaginal laxity was underreported, 95% believed vaginal laxity impacted patient sexual function, and 57% considered it to greatly affect quality of life. All respondents felt vaginal laxity was the dominant physical change experienced by subjects after vaginal delivery. As for treatment, all surveyed physicians recommended Kegel exercises along with physical therapy, with approximately 54% offering or recommending surgical intervention, although 83% of respondents were concerned about dyspareunia (painful sexual intercourse) as an associated risk of surgery.

Only recently have alternatives appeared to fill the wide gulf between the two ends of the spectrum. The term ‘vaginal rejuvenation’ has arisen, and received a lot of attention and scrutiny within the emergence of novel modalities. Vulvovaginal rejuvenation with devices harnessing laser or radiofrequency (RF) energy (among others), is a fairly new concept with real potential for success. Numerous studies in aesthetic medicine have demonstrated tissue contraction and determined a therapeutically ideal temperature range (40°C to 45°C) in which neocollagenesis (via the healing cascade) is stimulated without causing unnecessary damage to the skin or integral tissue structures.

A landmark study by Millheiser and colleagues in 2010\(^1\) investigated transurethral monopolar RF for vaginal laxity after vaginal childbirth. Subjects (n=24, age range 25 to 44) were premenopausal women and had at least one full term vaginal delivery. Investigators used a seven point vaginal laxity scale (vaginal laxity questionnaire, or VlQ) to assess subjective patient perception of laxity and improvement (with ratings of 1=very loose, 2=moderately loose, 3=slightly loose, 4=neither loose nor tight, 5=slightly tight, 6=moderately tight, and 7=very tight). A six point sexual satisfaction questionnaire (SSQ) was also administered to help evaluate perceived improvement in sexual satisfaction (rated as 1=none, 2=poor, 3=fair, 4=good, 5=very good, and 6=excellent). Cryogen cooling was used concurrently with the RF probe inside the vagina to manage potential unwanted thermal damage due to overtreatment. At 1 month post-treatment 67% of patients reported improvements of 2 to 4 points on the VlQ and all patients reported at least one point of improvement. By follow-up at 6 months, approximately 67% of subjects reported improvements of 2 to 4 points. Of the 12 subjects who had reported diminished sexual function following delivery, all reported notable improvement to sexual function as well.

Sekiguchi et al\(^*\) more recently reported on a prospective study of low-energy RF for vaginal introital laxity of 30 premenopausal women (age range 21 to 52 years), each receiving a 30-minute treatment with evaluations at 6 and 12 months post-treatment. Statistically significant improvements in sexual function, vaginal laxity, and reductions in distress during sexual activity were noted at 6 months and maintained through the 12 month endpoint, with no adverse events reported. RF has also been employed successfully to treat stress incontinence\(^1\).

Transcutaneous temperature controlled radiofrequency (TTCRF) brings with it numerous advantages for the treatment of skin laxity\(^5\). RF is an established modality for tissue tightening via stimulation of neocollagenesis, denaturation of collagen, contraction, and activation of the healing cascade. This was shown in a histological study of RF in animal studies\(^5\). Thus, tissue temperature is modulated by controlling the power (the electrical voltage delivered to the RF electrode) in relation to tissue impedance, which raises tissue temperature in the proximity of the RF electrode. Thermistors and thermocouples within the treatment probe provide feedback to the device, which controls power to modulate energy deposition and maximize therapeutic relevancy without causing damage and minimizing the potential for patient discomfort. Unlike laser-based treatments, skin type (color or pigmentation) is not an issue with RF energy, and while it is proven
effective on surface skin of the face and other body regions. RF is even more effective in tissue that is naturally moist and well hydrated, as is the vaginal and ancillary structures. Treatment is non-invasive and there is no downtime.

The treatment probe is of a proprietary design developed with expert physician input. During TTcRf treatment, the probe tip is passed back and forth slowly and with wide sweeps over the desired zone of treatment for 3 to 5 minutes, until the tissue is gradually heated to the therapeutically relevant level to induce tightening of the skin, mucosa, and fascia as well as stimulate neocollagenesis. This also promotes patient comfort and assures that the practitioner does not over-treat.

The purpose of the study is to evaluate the safety, tolerability, and clinical efficacy of TTcRf as well as anecdotally document possible ancillary beneficial effects of treatment, to promote further study.

**Patients and methods**

In this prospective study, 23 subjects (age range 26-58 years, mean 43.6; median vaginal births=2, mean parity 17.5; menopausal; 6 perimenopausal) presented with self-described mild to moderate primary or secondary vulvovaginal laxity. Associated secondary conditions (orgasmic dysfunction, stress incontinence, atrophic vaginitis) were present in most subjects. Those who presented with mild to moderate stress urinary incontinence (n=6) were evaluated by examination showing urethral hyper-mobility, positive Valsalva, and recording incontinence episodes per day along with pad counts. Severe incontinence patients with suspected ISD and positive empty bladder stress tests were excluded. Patients who complained of clinical significant atrophic vaginitis (n=8) were evaluated with symptoms of vaginal and vulvar dryness as well as painful intercourse and discomfort with their clothing.

Exclusion criteria included pelvic surgery within 5 years of study commencement, presence of major psychiatric conditions or related need for medication, chronic use of anti-inflammatory agents (including steroids) and immunosuppressants, pregnancy or planned pregnancy within the study period, recent abnormal Papnicolaou test result, presence of vulvar lesions or disease (dermatitis, human papillomavirus, herpes simplex, vulvar dystrophy), or the presence of any condition or circumstance that, in the opinion of the investigating physician, may be unsafe or otherwise interfere with the study. Informed consent was obtained from all subjects prior to commencement of the study.

Pre-treatment digital photography was performed at baseline along with physician evaluation of patients. Treatment was performed in a clinical office setting without anesthesia. During treatment, subjects were placed on a treatment table in the dorsal lithotomy position. A neutral return pad was placed underneath the buttocks of the subject, and a coupling gel was used as a lubricant for treatment with the TTcRf device. Once patients were settled and comfortable they were treated using the TTcRf device (ThermiVa, ThermiAesthetics, Inc., Southlake, TX) for approximately 5 minutes per zone (left and right labia majora, and the ventral, dorsal, left and right surfaces of the vaginal wall). The labia majora were treated first; the treatment tip was applied to each labial surface bilaterally from the lowest edge of the mons pubis to the perineal body and laterally to the crural folds. The clinical endpoint was achievement of the target temperature range of 40°C to 45°C for approximately 3-5 minutes per zone (or longer, depending on heat tolerance). Treatment was repeated every 4 to 9 cm into the cavity for each zone of the vaginal wall (ventral, dorsal, left and right). For each zone the treatment tip is inserted into the vagina with the emitter surface facing the desired direction, and energy is applied with the treatment cannula using an in-and-out motion. The clinical endpoint was achievement of the target temperature in the range of 40°C to 45°C for approximately 3-5 minutes per zone (or longer, depending on heat tolerance); treatment was repeated identically for each of the four vaginal surfaces. Total treatment time was less than 30 minutes. A complete course of therapy consisted of three treatments with the TTcRf device, at an interval of approximately 4-6 weeks. Patients were offered up to three treatments but not required to undergo all three.

**Table 2** Median score and improvement from baseline in vulvovaginal laxity and sexual satisfaction after TTcRf*

<table>
<thead>
<tr>
<th>BASELINE</th>
<th>10 DAYS POST TX1</th>
<th>TX2 (BEFORE TREATMENT)</th>
<th>TX3 (BEFORE TREATMENT)</th>
<th>30 DAYS POST TX3</th>
</tr>
</thead>
<tbody>
<tr>
<td>VLO‡</td>
<td>Score Improvement</td>
<td>Score Improvement</td>
<td>Score Improvement</td>
<td>Score Improvement</td>
</tr>
<tr>
<td>SSQ†</td>
<td>3</td>
<td>5</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>1.5</td>
<td>1.5</td>
<td>2.0</td>
<td>2.5</td>
</tr>
</tbody>
</table>

*Values expressed as median because data were not continuous and not normally distributed, median raw score and median improvement from baseline, thus, may not appear to agree.

†Vaginal Laxity Questionnaire [Millheiser 2010] rating vulvovaginal laxity on a seven-point scale where 1=very loose and 7=very tight.

‡Sexual Satisfaction Questionnaire [Millheiser 2010] rating sexual satisfaction on a six-point scale where 1=none and 6=excellent.

**Figure 3** (A) Before and (B) after images of nulliparous woman, age 52 years, presenting with severe laxity of the vagina and labia majora resulting in chronic irritation of the left majora, severe atrophic vaginitis, and anorgasmia. Outcome after two treatments with TTcRf included statistically significant improvement in laxity with visible aesthetic improvement and complete resolution of irritation, atrophic vaginitis, and anorgasmia.

"Treatment was performed in a clinical office setting without anesthesia."
Evaluation of vulvovaginal laxity was made on a 7 point scale by both the investigating physician and patient self-assessment via VLQ, the patient assessment data was used for analysis. A 6 point sexual satisfaction scale was also used by patients to rate sexual satisfaction. Table 1 delineates these scales.

Assessment occurred at baseline, 10 days after first treatment, before second treatment, before third treatment, and 30 days after the third treatment session. In addition, patients were asked to give a global assessment asking if they would recommend the procedure to a friend or family member (a 5 point scale where 1=strongly agree and 5=strongly disagree) and to rate overall satisfaction with the procedure (a 5 point scale where 1=very unsatisfied and 5=very satisfied).

Results

Of the original 23 subjects, 6 were lost to follow-up before each of the second and third treatments, reportedly due to high satisfaction with results not necessitating further treatment in the opinion of the patient. There were no burns, blisters or major complications during or after treatments, which were described as pleasant and very comfortable. All patients (n=23) received at least one treatment, with 17 undergoing a second treatment and 11 opting for a third. Average treatment time was approximately 10 minutes for the labia and 15 minutes for the vagina, totaling 25 minutes. Patients were able to resume all activity as normal, including sexual intercourse, immediately after each treatment.

The nature of the data (discrete, not continuous), necessitated the use of non-parametric statistical methods overall because data are not normally distributed with the traditional cut-off of p<0.05 for measure of statistical significance via Wilcoxon test, the Bonferroni correction was employed where appropriate, making the cut-off value for some data groups p<0.0125.

Statistically significant improvement in VLQ and SSQ scores from baseline were noted in all cases. Notably, while the patient VLQ assessment data was used for analysis, differences between patient and physician evaluation of vulvovaginal laxity were rare and overall found to be statistically insignificant (p=0.0001). Table 2 shows the median scores and level of improvement from baseline for the sake of comparison.

As seen in Table 2, the most pronounced improvement in VLQ is seen 10 days after the first treatment, with little difference noted before treatment two, suggesting that much of the result manifests rapidly. There is immediate visible correction after treatment with additional effect over time. There is some additional improvement with a second treatment, and minimal improvement with a third treatment. A similar trend can be seen for the SSQ results. It should be noted that improvement in VLQ score between sessions two and three was also statistically significant, if modest.

The overall results also correlate with patient behavior. Six patients did not return for a second treatment, and 6 opted out after two treatments, happy with results and seeing no need for further treatment.

All patients finishing a full course of treatment reported that they were very satisfied and strongly agreed that they’d recommend the procedure (scores of 5 on both global assessments).

Discussion

The tightening result is visible immediately after the first treatment and the full outcome takes a few months to fully manifest regardless of the number of sessions, but after even a single treatment the median change in the VLQ score was 3 points on a 7 point scale at the second treatment visit. Median change in SSQ score during that time was more modest but still notable (1.5). As demonstrated in those patients (n=17) electing to undergo at least one more treatment, median change in VLQ score showed that the strongest improvement occurred after the first treatment but additional, statistically significant improvement was available with a second and third session. Improvement measured by self-reported SSQ improved similarly but much less dramatically after the first session. It may be that after the first treatment pronounced improvement is perceived, with any additional improvement in sexual satisfaction appearing minimal with additional treatment, likely due to the challenge associated with self-assessment of sexual satisfaction. Small, incremental rises are less noticeable but were still reported by some patients. Overall this suggests that while one or two sessions may be
Key points

1. TTCRF is safe and comfortable with superior tightening effects for vulvar and vaginal laxity that can approach pre-pregnancy and pre-menopausal levels

2. TTCRF is effective for both external and internal atrophic vulvovaginitis

3. TTCRF is effective in reducing both SUI and OAB symptoms

4. TTCRF is effective for orgasmic dysfunction in selective patients

5. Clinical effectiveness with no downtime is seen after 1 treatment and improves over 3 months

6. Yearly to bi-yearly maintenance treatment is effective in maintaining achieved RF effects

Based on the data, TTCRF is safe, tolerable and effective for vulvovaginal rejuvenation.

Estimated satisfaction, a second session may still offer some benefit. A third may not be necessary but continued improvement may be expected. An additional study with larger populations examining protocol refinements may reveal more ideal treatment parameters and further delineate persistence of outcomes.

In addition to offering some confirmation of the results shared in the studies by Milheiser and Sekoguchi, this investigation of TTCRF brings two additional factors into light: the treatment of the labia majora, and the use of temperature control feedback to maximize delivered energy safely. Tightening of the labia majora contributes to the positive perception of aesthetic improvement, as demonstrated by before and after photography (Figures 1, 2 and 3). Real-time feedback by which the device modulates power and thus maintains safe temperatures without cooling or anesthesia, is a boon to successful treatment and may represent a key advance in the emerging field of vulvovaginal rejuvenation. Users can rapidly treat patients with little preparation. Office time for the investigating physician. The mechanism of action for the investigating physician. The mechanism of action for


**References**


Declaration of interest This study and preparation of this research article was funded in part by ThermiAesthetics, Inc., manufacturer of the TTCRF technology used during the investigation.